Is Cbay stock a buy?
Isabella Wilson 
Out of 3 analysts, 2 (66.67%) are recommending CBAY as a Strong Buy, 1 (33.33%) are recommending CBAY as a Buy, 0 (0%) are recommending CBAY as a Hold, 0 (0%) are recommending CBAY as a Sell, and 0 (0%) are recommending CBAY as a Strong Sell. What is CBAY’s earnings growth forecast for 2021-2023?
Who owns Cbay stock?
Top 10 Owners of Cymabay Therapeutics Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 5.22% | 3,598,748 |
| Commodore Capital LP | 5.12% | 3,529,465 |
| Baker Bros. Advisors LP | 3.15% | 2,170,464 |
| Millennium Management LLC | 2.98% | 2,053,779 |
Why is Cbay stock falling?
Shares of CymaBay Therapeutics (NASDAQ:CBAY) fell over 76% today after the company announced that it was halting the development of its lead drug candidate, seladelpar, in primary biliary cholangitis (PBC). As of 3:09 p.m. EST, the pharma stock had settled to a 76.2% loss.
Is CymaBay stock a buy?
CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Is CymaBay a good buy?
CymaBay Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Is CTXR a good buy?
Out of 2 analysts, 2 (100%) are recommending CTXR as a Strong Buy, 0 (0%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell. What is CTXR’s earnings growth forecast for 2021-2023?
Will TXMD go up?
The 4 analysts offering 12-month price forecasts for TherapeuticsMD Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 4.00. The median estimate represents a +437.40% increase from the last price of 0.93.
What is the stock price of CymaBay Therapeutics?
This stock option grant has an exercise price of $4.37 per share, which is equal to the closing price of CymaBay’s common stock on May 17, 2021, the date of grant for the stock option.
Who is dr.kim of CymaBay Therapeutics?
Kim is a physician-scientist trained in endocrinology who brings significant clinical development and executive experience in emerging biotech environments from companies such as Amylin, Orexigen and Zafgen. Dr.
What kind of clinical trials is Cymabay in?
CymaBay also continued to make significant progress conducting the development program for seladelpar in primary biliary cholangitis (PBC). With clinical sites activated in North America and Europe, patient recruitment is underway in RESPONSE, a global Phase 3 registrational study evaluating seladelpar in patients with PBC.
Who is the Chief Medical Officer of CymaBay?
In May 2021, CymaBay strengthened its management team with the additions of Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer. CymaBay also continued to make significant progress conducting the development program for seladelpar in primary biliary cholangitis (PBC).
